重组组织型纤溶酶原激活剂静脉溶栓桥接机械取栓治疗急性脑梗死效果分析

Clinical effect analysis of intravenous infusion of recombinant tissuetype plasminogen activator combined with mechanical thrombectomy for acute cerebral infarction

目的探讨重组组织型纤溶酶原激活剂静脉溶栓桥接机械取栓治疗急性脑梗死的效果。方法选取临汾市人民医院2016年7月至2018年7月收治的100例急性脑梗死患者为研究对象,采用随机数字表法将其分为研究组与对照组,每组50例。两组急性脑梗死患者均予以临床常规治疗,对照组在常规治疗基础上加用重组组织型纤溶酶原激活剂静脉溶栓治疗,研究组在常规治疗基础上加用重组组织型纤溶酶原激活剂静脉溶栓桥接机械取栓。采用美国国立卫生研究院卒中量表(NIHSS)评价两组患者治疗后当天及治疗后2周神经功能变化情况,分析比较两组预后。结果对照组与研究组治疗后当天NIHSS量表评分比较差异未见统计学意义(P>0.05);治疗后2周两组NIHSS量表评分均较之前显著下降,且研究组神经功能改善效果优于对照组,差异有统计学意义(P<0.05)。研究组7 d内症状性颅内出血率(4.00%)、2周内病死率(2.00%)均低于对照组(22.00%,18.00%),P<0.05。结论经重组组织型纤溶酶原激活剂静脉溶栓桥接机械取栓治疗急性脑梗死效果显著,有利于保障患者的生活质量及生命安全。

Objective To investigate the practical effects of intravenous infusion of recombinant tissuetype plasminogen activator combined with mechanical thrombectomy on acute cerebral infarction. Methods One hundred patients with acute cerebral infarction who were hospitalized in Linyi People’s Hospital from July 2016 to July 2018 were selected as research objects. And the included patients were divided into observation group and control group according to random number table method, with 50 cases in each group. All patients were treated by conventional therapy;while patients in control group were treated by intravenous infusion of recombinant tissuetype plasminogen activator on the basis of conventional treatment;additionally, patients in observation group were treated by intravenous infusion of recombinant tissuetype plasminogen activator combined with mechanical thrombectomy. Nerve function was evaluated by National Institute of Health stroke scale (NIHSS) on the day after treatment and 2 weeks after treatment, and the prognoses were compared between the two groups. Results There was no significant difference in NIHSS scores between the two groups on the day after treatment (P>0.05);and NIHSS scores of the two groups were decreased 2 weeks after treatment, but the improvement in nerve function of observation group was significantly better than that of control group (P<0.05). The symptomatic intracranial hemorrhage rate within 7 days after treatment (4.00%), mortality within 2 weeks (2.00%) of study group were significantly lower than those of control group (22.00%, 18.00%), P<0.05. Conclusions Intravenous infusion of recombinant tissuetype plasminogen activator combined with mechanical thrombectomy has remarkable effects on acute cerebral infarction, which is conducive to ensuring the safety and quality of life.